

ASX Release

SUDA SIGNS A CO-DEVELOPMENT DEAL WITH LABORATORIOS ORDESA S.L.

- **SUDA and Ordesa will undertake a feasibility study on a well-known consumer brand using SUDA's OroMist technology;**
- **The two companies will jointly own the intellectual property that arises out of the study;**
- **SUDA to receive an upfront option fee of US\$100,000.**

PERTH, AUSTRALIA – 5 December 2019: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today announces that it has entered into a fully-funded, feasibility study and option agreement with Laboratorios Ordesa, S.L., (Ordesa) a Spanish pharmaceutical company that focuses on nutrition, health and well-being.

The two companies intend to co-develop a major consumer product for the paediatric market which SUDA anticipates will benefit from an improved patient delivery route and which could, potentially, also benefit from the OroMist technology superiority in speed of onset of action and less drug being required.

The feasibility study will be fully funded by Ordesa and SUDA will receive an upfront option fee of US\$100,000 (approx. A\$140,000).

On the successful completion of the initial feasibility study, or as agreed by the parties, Ordesa may elect to expand the scope of work or to exercise its option for a full development of the product which is to be funded by Ordesa. The two companies will negotiate a definitive agreement for the development, licence and supply of the product.

All intellectual property from the feasibility study and the full development will be jointly owned, however, the trademark of the product will be the property of Laboratorios Ordesa. SUDA and Ordesa will work together through joint committees to manage the development and the commercialisation of the product.

Mr David Phillips, SUDA's Executive Director of Business Development, commented: "This is a very exciting deal which combines the consumer marketing expertise of Ordesa with SUDA's formulation spray technology and pharmaceutical partnering capability".

Further information:

Paul Hopper

EXECUTIVE CHAIRMAN

SUDA Pharmaceuticals Ltd

Tel: +61 (0) 406 671 515

phopper@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; PAH; epileptic seizures and pre-procedural anxiety and cancer.

For more information, visit www.sudapharma.com

About Laboratorios Ordesa S.L

With a history of more than 75 years offering the best products in infant feeding, Laboratorios Ordesa leads the market with solutions for all stages. More than two generations of Spanish babies have been fed with Blemil and Blevit baby milk and cereals, in addition to offering a wide range of nutritional supplements that cover the entire paediatric age and Pediatopic, a new line for child atopic skin care. Moreover, Laboratorios Ordesa has the range of products for women DONNAplus and the range of nutritional supplements for adults with FontActiv and Colnatur, a hydrolysed collagen brand. Nowadays, Laboratorios Ordesa has a staff of around 330 people and a product portfolio containing over 400 items. One of the keys to the growth of Laboratorios Ordesa has been its commitment to international expansion. It's currently operating in more than 20 countries in Europe, the Middle East, Latin America, Africa and Asia.

Visit us: www.ordesa.es